Provider Briefing: Catapres (Clonidine) Supply in 2026

Clonidine remains one of the most versatile medications in clinical practice — prescribed across primary care, psychiatry, pediatrics, addiction medicine, and cardiology. When supply tightens, the ripple effects touch multiple patient populations.

This article provides a concise overview of the current Clonidine supply landscape, prescribing considerations during shortages, and tools to help your patients access their medication.

Shortage Timeline

Clonidine's supply history has been largely stable for oral formulations, with notable disruptions concentrated in transdermal products:

• 2018–2019: Some Clonidine formulations appeared on the FDA Drug Shortages database, primarily affecting certain tablet strengths and patch sizes
• 2020–2023: Intermittent Catapres-TTS patch supply disruptions as pandemic-era supply chain issues affected specialized manufacturers
• 2024–2025: Patch availability remained inconsistent; generic oral tablet supply stabilized with additional market entrants
• Early 2026: Generic Clonidine tablets are generally well-supplied. Catapres-TTS patches continue to experience periodic availability gaps due to limited manufacturing capacity

Prescribing Implications

Formulation Considerations

When patients report difficulty filling prescriptions, the formulation matters:

• Immediate-release tablets (0.1 mg, 0.2 mg, 0.3 mg): Multiple generic manufacturers; generally available. This is the most reliable formulation to prescribe during supply disruptions.
• Extended-release tablets (Kapvay, generic): Availability is moderate. If ADHD is the indication, extended-release Guanfacine (Intuniv) may be more reliably available.
• Transdermal patches (Catapres-TTS): Most supply-vulnerable formulation. Consider converting to oral tablets when clinically appropriate. Dose conversion: Catapres-TTS-1 (0.1 mg/day) ≈ 0.1 mg PO BID.
• Oral suspension (Onyda XR): Limited distribution; consider for patients who cannot swallow tablets.

Critical Safety Reminder

When switching formulations or if patients experience a gap in therapy, rebound hypertension is a significant risk. Patients on Clonidine should never abruptly discontinue. When transitioning between formulations:

• Overlap therapy when possible (e.g., start oral tablets before removing patch)
• Taper gradually if discontinuing — reduce dose by 0.1 mg every 3-7 days
• Monitor blood pressure closely during transitions
• Counsel patients explicitly about the dangers of abrupt cessation

Current Availability Picture

As of Q1 2026:

• Generic Clonidine IR tablets: Adequate supply nationally. Multiple manufacturers (Teva, Mylan/Viatris, Aurobindo, others) are producing. Most pharmacies can fill within 1-2 business days.
• Generic Clonidine ER tablets: Moderate supply. Some strengths may require ordering.
• Catapres-TTS patches: Intermittent availability. Patients may need to check multiple pharmacies or switch to oral formulations.

For real-time availability data, Medfinder for Providers allows you to check pharmacy-level stock across your patient's area.

Cost and Access Considerations

Clonidine is among the most affordable prescription medications available:

• Generic tablets: $4–$15/month without insurance; included in many $4 generic programs (Walmart, Kroger, Costco)
• Generic ER tablets: $30–$100/month without insurance
• Catapres-TTS patches: $150–$400+/month for brand; $80–$200 for generic when available

For patients facing cost barriers:

• NeedyMeds and RxAssist maintain directories of patient assistance programs
• GoodRx, SingleCare, and other discount cards can reduce cash prices significantly
• Most insurance formularies list generic Clonidine as Tier 1 with low copays
• Brand-name Catapres-TTS may require prior authorization

For a patient-facing guide on savings: How to Save Money on Catapres.

Tools and Resources for Providers

• Medfinder for Providers: Real-time pharmacy availability search — help patients find their specific formulation in stock near them
• FDA Drug Shortages Database: Check the current federal shortage status for all Clonidine formulations
• ASHP Drug Shortage Resource Center: Provides alternative therapy recommendations during active shortages

Alternative Agents

When Clonidine is unavailable or poorly tolerated, consider:

• Guanfacine (Tenex/Intuniv): Same class (alpha-2 agonist). Longer half-life, once-daily dosing, potentially less sedation. Intuniv is FDA-approved for ADHD in children/adolescents.
• Methyldopa: Centrally acting; preferred in pregnancy-related hypertension
• Hydrochlorothiazide: First-line for hypertension if the indication is blood pressure alone
• Amlodipine: Widely available calcium channel blocker; once-daily, well-tolerated

Note that for off-label uses (anxiety, withdrawal management, insomnia), Guanfacine is typically the closest therapeutic alternative.

For detailed alternatives information: Alternatives to Catapres.

Looking Ahead

The oral Clonidine tablet market is well-positioned heading through 2026, with robust generic competition keeping supply stable and prices low. The transdermal patch market remains fragile due to limited manufacturers.

Providers should proactively discuss backup plans with patients who rely on patches, including willingness to convert to oral therapy if needed. Documenting a patient's preferred formulation and acceptable alternatives in the chart can save time during future refill disruptions.

Final Thoughts

Clonidine supply is generally adequate in 2026 for oral formulations, but patch availability continues to be unreliable. Proactive planning — including establishing alternative formulations, using real-time availability tools like Medfinder for Providers, and counseling patients about safe tapering — will help your patients avoid dangerous gaps in therapy.

For additional clinical guidance, see our companion article: How to Help Your Patients Find Catapres in Stock.